The effect of rosiglitazone on the liver: Decreased gluconeogenesis in patients with type 2 diabetes

被引:56
作者
Gastaldelli, A
Miyazaki, Y
Pettiti, M
Santini, E
Ciociaro, D
DeFronzo, RA
Ferrannini, E
机构
[1] Natl Res Ctr, Inst Clin Physiol, Metab Unit, I-56100 Pisa, Italy
[2] Univ Pisa, Sch Med, Dept Internal Med, I-56100 Pisa, Italy
[3] Univ Texas, Hlth Sci Ctr, Diabet Div, San Antonio, TX 78229 USA
关键词
D O I
10.1210/jc.2005-1159
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/Hypothesis: Diabetic hyperglycemia results from insulin resistance of peripheral tissues and glucose overproduction due to increased gluconeogenesis (GNG). Thiazolidinediones have been shown to improve glycemic control and increase peripheral insulin sensitivity. Whether chronic thiazolidinedione treatment is associated with a decrease in GNG has not been determined. Materials and Methods: We studied 26 diet-treated type 2 diabetic patients randomly assigned to rosiglitazone (RSG; 8 mg/d; n=13) or placebo (n=13) for 12 wk. At baseline and 12 wk, we measured endogenous glucose production (by [H-3] glucose infusion) and GNG( by the [H-2](2)O technique) after a 15-h fast. Peripheral insulin sensitivity was evaluated by a two-step (240 and 960 pmol/min/m(-2)) euglycemic insulin clamp. Results: Compared with placebo, RSG reduced fasting plasma glucose (9.7 +/- 0.7 to 7.4 +/- 0.3 mmol/ liter; P<0.001), fasting fractional GNG (-15 +/- 4%; P=0.002), and fasting GNG flux (-3.9 +/- 1.2 mu mol/min/kg fat-free mass; P=0.004), with no effect on glycogenolytic flux. Changes in GNG flux and fasting glucose were tightly correlated (r=0.83; P<0.0001). During both clamp steps, RSG enhanced insulin-mediated glucose clearance (by 26% and 31%; P=0.01 and P<0.02, respectively). In a subgroup of patients studied with magnetic resonance imaging, the reduction in GNG flux was correlated (r=0.65; P<0.02) with the reduction in visceral fat area. Conclusion/Interpretation: RSG increases peripheral tissue insulin sensitivity and decreases endogenous glucose release via an inhibition of gluconeogenesis.
引用
收藏
页码:806 / 812
页数:7
相关论文
共 47 条
[21]   MEASUREMENT OF ABDOMINAL FAT WITH T1-WEIGHTED MR IMAGES [J].
LANCASTER, JL ;
GHIATAS, AA ;
ALYASSIN, A ;
KILCOYNE, RF ;
BONORA, E ;
DEFRONZO, RA .
JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING, 1991, 1 (03) :363-369
[22]   Contributions of gluconeogenesis to glucose production in the fasted state [J].
Landau, BR ;
Wahren, J ;
Chandramouli, V ;
Schumann, WC ;
Ekberg, K ;
Kalhan, SC .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (02) :378-385
[23]   Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus [J].
Mäkimattila, S ;
Nikkilä, K ;
Yki-Järvinen, H .
DIABETOLOGIA, 1999, 42 (04) :406-412
[24]   Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients [J].
Miyazaki, Y ;
Mahankali, A ;
Matsuda, M ;
Mahankali, S ;
Hardies, J ;
Cusi, K ;
Mandarino, LJ ;
DeFronzo, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (06) :2784-2791
[25]   Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients [J].
Miyazaki, Y ;
Glass, L ;
Triplitt, C ;
Matsuda, M ;
Cusi, K ;
Mahankali, A ;
Mahankali, S ;
Mandarino, LJ ;
DeFronzo, RA .
DIABETOLOGIA, 2001, 44 (12) :2210-2219
[26]   Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone [J].
Miyazaki, Y ;
Mahankali, A ;
Matsuda, M ;
Glass, L ;
Mahankali, S ;
Ferrannini, E ;
Cusi, K ;
Mandarino, LJ ;
DeFronzo, RA .
DIABETES CARE, 2001, 24 (04) :710-719
[27]   Determinants of postabsorptive endogenous glucose output in non-diabetic subjects [J].
Natali, A ;
Toschi, E ;
Camastra, S ;
Gastaldelli, A ;
Groop, L ;
Ferrannini, E .
DIABETOLOGIA, 2000, 43 (10) :1266-1272
[28]   Vascular effects of improving metabolic control with melformin or rosiglitazone in type 2 diabetes [J].
Natali, A ;
Baldeweg, S ;
Toschi, E ;
Capaldo, B ;
Barbaro, D ;
Gastaldelli, A ;
Yudkin, JS ;
Ferrannini, E .
DIABETES CARE, 2004, 27 (06) :1349-1357
[29]  
Nielsen S, 2004, J CLIN INVEST, V113, P1582, DOI 10.1172/JCI21047
[30]   Acute effects of pioglitazone on glucose metabolism in perfused rat liver [J].
Nishimura, Y ;
Inoue, Y ;
Takeuchi, H ;
Oka, Y .
ACTA DIABETOLOGICA, 1997, 34 (03) :206-210